NCI-CCC Neuroendocrine Tumor Board

Questions discussed in this category

For patients with well differentiated NET whose carcinoid symptoms are controlled on SSAs but have persistently elevated 5HIAA, would you consider adding telotristat for prevention of carcinoid heart disease?

How aggressive should we be in bringing elevated plasma/urine 5HIAA to normal levels in patients whose symptoms are controlled? Before we have the res...

1 Answer available

How would you approach adjuvant therapy for a patient with resected T4N1 high grade large cell neuroendocrine tumor of the cecum with adenocarcinoma component?

Pathology details: 75% high grade large cell neuroendocrine tumor of the cecum (20-30 mitoses per 10 hpf, Ki67 75%) and 25% adenocarcinoma. Patient ha...

1 Answer available

Do you prefer carboplatin or cisplatin with etoposide for stage IV extra-pulmonary neuroendocrine carcinomas with a Ki-67 > 55%?

1 Answer available

Would you consider PRRT re-treatment in a patient with a well differentiated NET previously treated with 4 cycles of PRRT?

2 Answers available

What is the role of liver transplant in NET?

3 Answers available

Papers discussed in this category

Am J Transplant, 2016 Jun 09

The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors.

Transplantation, 2021 Apr 27

Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors.

Surgery, 2017 Jun 16

Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review.

JAMA Oncol, 2020 Apr 16

Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.

Eur J Nucl Med Mol Imaging, 2018 Sep 28

Salvage peptide receptor radionuclide therapy with [Lu-DOTA,Tyr]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

Br J Radiol, 2018 Mar 20

Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response.

Eur J Nucl Med Mol Imaging, 2013 Sep 13

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours.

BMC Cancer, 2019 Aug 08

Salvage PRRT with Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival.

Scand J Gastroenterol, 2021 Jan 20

Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study.

Int J Endocrinol, 2021 Jan 23

The Safety and Efficacy of the Repeated PRRT with [Y]Y/[Lu]Lu-DOTATATE in Patients with NET.

Cancer Treat Rev, 2020 Dec 22

Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.

Circulation, 1995-08-15

Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

Endocrine-related cancer, 2018-03

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.

Ann. Surg., 2019 Aug 30

Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas.

Annals of surgical oncology, 2019-04

Survival in Patients with High-Grade Colorectal Neuroendocrine Carcinomas: The Role of Surgery and Chemotherapy.

Related Topics